Clinical trial NCT04717414: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Official title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Myeloproliferative Disorders
Myelofibrosis
Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Anemia
Keywords: Luspatercept
ACE-536
Myeloproliferative Neoplasm
Myelofibrosis
JAK2
Red blood cell transfusion
Post-ET MF
Post-PV MF
Reblozyl
Anemia
Lead sponsor: Celgene
Sponsor class: INDUSTRY
First posted: 2021-01-22
Enrollment: 309
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions.

The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period.

Following the Day 169 Response Assessment, subjects who did not show clinical benefit will have the option to unblind. Subjects who were on placebo during the Blinded Core Treatment Period will have the opportunity to crossover into the Open-Label Extension Treatment Period and receive Luspatercept.

Detailed description: Permitted Concomitant Medications and Procedures

* Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their respective label and as prescribed as part of the subject's standard-of-care therapy as prescribed by their physician prior to study entry.
* Best supportive care (BSC) includes, but is not limited to, treatment with transfusions (eg, RBC, platelet, whole blood), ICTs, antibiotic, antiviral and/or antifungal therapy, and nutritional support as needed.
* Granulocyte colony-stimulating factors (ie, G-CSF, granulocyte macrophage colony-stimulating factor \[GM-CSF\]) are allowed only in cases of neutropenic fever or as clinically indicated per product label.
* Prophylactic antithrombotic therapy is permitted.
* Thrombopoietin and platelet transfusions are permitted.
* Treatment with systemic corticosteroids is permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone during the study.
* Administration of attenuated vaccines (eg, influenza vaccine) is allowed if clinically indicated per Investigator discretion.
* Iron chelation therapy (ICT) is to be used according to the product label. If the label permits, the ICT dose should be stable during at least the first 24 weeks of IP. Initiation of ICT while within the first 24 weeks of IP should be clinically indicated to treat an AE.

Prohibited Concomitant Medications

The following concomitant medications are specifically excluded during the course of study treatment:

* Cytotoxic, chemotherapeutic, targeted, or investigational agents/therapies (excluding JAK2 inhibitor therapy)
* Azacitidine, decitabine, or other hypomethylating agents
* Lenalidomide, thalidomide, and pomalidomide
* Erythropoietin stimulating agents (ESAs) and other RBC hematopoietic growth factors (eg, IL-3)
* Hydroxyurea or other alkylating agents
* Androgens (unless given to treat hypogonadism)
* Oral retinoids (topical retinoids are permitted)
* Arsenic trioxide
* Interferon
* Anagrelide
* Systemic corticosteroids at a dose equivalent to \> 10 mg prednisone
* Investigational products for the treatment of MPN-associated MF

Eligibility criteria: Subjects must satisfy the following criteria to be randomized in the study:

Inclusion Criteria

- Subject is ≥18 years of age at the time of signing the ICF.

* Subject has a diagnosis of PMF according to the 2016 World Health Organization (WHO) criteria or diagnosis of post-ET or post-PV MF according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report.
* Subject is requiring RBC transfusions as defined as:.

  i) Average RBC-transfusion frequency: 4 to 12 RBC units/12 weeks immediately up to randomization. There must be no interval \> 6 weeks (42 days) without ≥ 1 RBC transfusion.

ii) RBC transfusions are scored in determining eligibility when given for treatment of:.

A. Symptomatic (ie, fatigue or shortness of breath) anemia with a pretransfusion Hgb ≤ 9.5 g/dL or.

B. Asymptomatic anemia with a pretransfusion Hgb ≤ 7 g/dL.

iii) RBC transfusions given for worsening of anemia due to bleeding or infections are not scored in determining eligibility.

- Subjects on continuous (eg, absent of dose interruptions lasting ≥ 2 consecutive weeks) JAK2 inhibitor therapy as approved in the country of the study site for the treatment for MPN-associated MF as part of their standard-of-care therapy for at least 32 weeks, on stable daily dose for at least 16 weeks immediately up to the date of randomization and anticipated to be on a stable daily dose of that JAK2 inhibitor for at least 24 weeks after randomization.

* Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2.
* A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP)participating in the study must:.

  i) Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the subject practices true abstinence\* from heterosexual contact.

ii) Either commit to true abstinence\* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception\*\* without interruption, 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy.

- Male subjects must: Practice true abstinence\* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential\*\* while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) following IP discontinuation, even if he has undergone a successful vasectomy.

i) True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the subject. \[Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.\].

ii) Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Combined (estrogen and progestogen containing) hormonal contraception: Oral, Intravaginal, Transdermal; Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral, Injectable hormonal contraception, Implantable hormonal contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence.

* Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
* Subject is willing and able to adhere to the study visit schedule and other protocol requirements including the use of the electronic patient reported outcomes device.

Exclusion Criteria

* The presence of any of the following will exclude a subject from randomization:.
* Subject with anemia from cause other than MPN-associated MForJAK2 inhibitor therapy (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infection, or any type of known clinically significant bleeding or sequestration).
* Subject use of hydroxyurea, immunomodulatory compounds such as pomalidomide, thalidomide, ESAs, androgenic steroids or other drugs with potential effects on hematopoiesis ≤ 8 weeks immediately up to the date of randomization.

  i) Systemic corticosteroids are permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone for the 4 weeks immediately up to randomization.

ii) Iron chelation therapy (ICT) is permitted providing the subject is receiving a stable dose for the 8 weeks immediately up to randomization.

- Subject with any of the following laboratory abnormalities at screening:.

i) Neutrophils: \< 1 x 10\^9/L.

ii) White blood count (WBC): \> 100 x 10\^9/L.

iii) Platelets: the lowest allowable level as approved for the concomitant JAK2 inhibitor but not \< 25 x 10\^9/L or \> 1000 x 10\^9/L.

iv) Peripheral blood myeloblasts:\> 5%.

v) Estimated glomerular filtration rate:\< 30 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease \[MDRD\] formula) or nephrotic subjects (eg, urine albumin-to-creatinine ratio \> 3500 mg/g).

vi) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):\> 3.0 x upper limit of normal (ULN).

vii) Direct bilirubin: ≥ 2 x ULN.

A. Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (eg, ineffective erythropoiesis).

* Subject with uncontrolled hypertension, defined as repeated elevations of systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, that is not resolved at the time of randomization.
* Subject with prior history of malignancies, other than disease under study, unless the subject has been free of the disease for ≥ 3 years. However, subject with the following history/concurrent conditions is allowed:.

  i) Basal or squamous cell carcinoma of the skin.

ii) Carcinoma in situ of the cervix.

iii) Carcinoma in situ of the breast.

iv) Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \[TNM\] clinical staging system).

* Subject with prior hematopoietic cell transplant or subject anticipated to receive a hematopoietic cell transplant during the 24 weeks from the date of randomization. 7. Subject with stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months immediately up to the date of randomization.
* Subject with major surgery within 2 months up to the date of randomization. Subject must have completely recovered from any previous surgery immediately up to the date of randomization.
* Subject with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of ≥ 2 units of packed red cells) in the last 6 months prior to the date of randomization.
* Subject with inadequately controlled heart disease and/or have a known left ventricular ejection fraction \< 35%.
* Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
* Subject with known human immunodeficiency virus (HIV), evidence of active Hepatitis B (HepB) as demonstrated by the presence of Hepatitis B surface antigen (HBsAg) and/or positive for Hepatitis B virus DNA (HBVDNA-positive), and/or evidence of active Hepatitis C (HepC) as demonstrated by a positive Hepatitis C virus RNA (HCV-RNA) test of sufficient sensitivity.
* Subject with prior therapy of luspatercept or sotatercept.
* Subject with history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product.
* Pregnant or breastfeeding females.
* Subject participation in any other clinical protocol or investigational trial that involves use of experimental therapy (including investigational agents) and/or therapeutic devices within 30 days or for investigational agents within five half-lives, whichever comes later, immediately up to the date of randomization.
* Subject with any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study or places the subject at unacceptable risk if he/she were to participate in the study. 18.Subject with any condition or concomitant medication that confounds the ability to interpret data from the study.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Primary outcomes:
measure: Red blood cell-transfusion independence (RBC-TI) ≥ 12 weeks (RBC-TI 12)
timeFrame: Up to 24 weeks
Secondary outcomes:
measure: Red blood cell-transfusion independence ≥ 16 weeks (RBC-TI 16)
timeFrame: Up to 24 weeks
measure: Duration of Red blood cell-transfusion independence (RBC-TI 12)
timeFrame: Up to end of treatment, approximately 3 years
measure: Reduction of transfusion burden by ≥ 50% and by ≥ 4 units/12 weeks from baseline over any consecutive 12-week period
timeFrame: Up to 24 weeks
measure: Duration of reduction in transfusion burden
timeFrame: Up to end of treatment, approximately 3 years
measure: Red blood cell-transfusion independence ≥ 12 weeks in the treatment period (RBC-TI 12/TP)
timeFrame: Up to end of treatment, approximately 3 years
measure: Red blood cell-transfusion independence ≥ 16 weeks in the treatment period (RBC-TI 16/TP)
timeFrame: Up to end of treatment, approximately 3 years
measure: Change in RBC transfusion burden
timeFrame: Up to 24 weeks
measure: Cumulative duration of RBC-transfusion independence
timeFrame: Up to end of treatment, approximately 3 years
measure: Mean Hgb increase ≥ 1 g/dL from baseline over any consecutive 12-week period in absence of RBC transfusions
timeFrame: Up to end of treatment, approximately 3 years
measure: Change in serum ferritin from baseline
timeFrame: Up to end of treatment, approximately 3 years
measure: Incidence of Adverse Events (AEs)
timeFrame: From screening up to 42 days post last dose
measure: Transformation to blast phase: Number of subjects who transform into AML
timeFrame: Up to approximately 5 years
measure: Frequency of Antidrug antibodies (ADA)
timeFrame: From randomization and up to including 48 weeks post first dose
measure: Pharmacokinetics - Area Under the Concentration-Time Curve (AUC)
timeFrame: From randomization and up to including 48 weeks post first dose
measure: Pharmacokinetics - Maximum plasma concentration of drug (Cmax)
timeFrame: From randomization and up to including 48 weeks post first dose
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Local Institution - 110
state: California
city: Orlando
country: United States
facility: Local Institution - 135
state: Florida
city: Plantation
country: United States
facility: Local Institution - 133
state: Florida
city: Chicago
country: United States
facility: Local Institution - 112
state: Illinois
city: Lexington
country: United States
facility: Local Institution - 124
state: Kentucky
city: Ann Arbor
country: United States
facility: Local Institution - 114
state: Michigan
city: Saint Louis
country: United States
facility: Local Institution - 108
state: Missouri
city: Hackensack
country: United States
facility: John Theurer Cancer Center
state: New Jersey
city: New York
country: United States
facility: Mount Sinai Medical Center
state: New York
city: Pittsburgh
country: United States
facility: University of Pittsburg Medical Center
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Allegheny Health Network
state: Pennsylvania
city: Knoxville
country: United States
facility: Local Institution - 130
state: Tennessee
city: Houston
country: United States
facility: The University of Texas - MD Anderson Cancer Center
state: Texas
city: Salt Lake City
country: United States
facility: Local Institution - 119
state: Utah
city: Ciudad Autónoma de BuenosAires
country: Argentina
facility: Local Institution - 172
state: Buenos Aires
city: La Plata
country: Argentina
facility: Hospital Italiano de La Plata
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: Hospital Italiano de Buenos Aires
city: Clayton
country: Australia
facility: Monash Medical Centre
state: Victoria
city: Melbourne
country: Australia
facility: The Alfred Hospital
state: Victoria
city: Nedlands
country: Australia
facility: Sir Charles Gairdner Hospital
state: Western Australia
city: Gosford
country: Australia
facility: Gosford Hospital
city: Hobart
country: Australia
facility: Royal Hobart Hospital
city: Graz
country: Austria
facility: Local Institution - 272
city: Linz
country: Austria
facility: Krankenhaus der Elisabethinen Linz, I Interne Abteilung
city: Vienna
country: Austria
facility: Local Institution - 271
city: Vienna
country: Austria
facility: Local Institution - 274
city: Brugge
country: Belgium
facility: Local Institution - 318
city: Brussels
country: Belgium
facility: Local Institution - 312
city: Hasselt
country: Belgium
facility: Local Institution - 313
city: Leuven
country: Belgium
facility: Uz Leuven
city: Liège
country: Belgium
facility: Local Institution - 319
city: Roeselare
country: Belgium
facility: Local Institution - 316
city: Verviers
country: Belgium
facility: Local Institution - 315
city: Yvoir
country: Belgium
facility: Cliniques Universitaires UCL de Mont-Godine
city: Calgary
country: Canada
facility: Local Institution - 181
state: Alberta
city: Edmonton
country: Canada
facility: Local Institution - 179
state: Alberta
city: Vancouver
country: Canada
facility: Local Institution - 183
state: British Columbia
city: London
country: Canada
facility: University Hospital - London Health Sciences Centre
state: Ontario
city: Toronto
country: Canada
facility: Local Institution - 180
state: Ontario
city: Montreal
country: Canada
facility: Local Institution - 177
state: Quebec
city: Montreal
country: Canada
facility: Sir Mortimer B. Davis - Jewish Genl
state: Quebec
city: Sherbrooke
country: Canada
facility: Local Institution - 176
state: Quebec
city: La Serena
country: Chile
facility: IC La Serena Research
state: Coquimbo
city: Las Condes
country: Chile
facility: Local Institution - 192
state: Metropolitana De Santiago
city: Santiago
country: Chile
facility: Local Institution - 193
city: Guangzhou
country: China
facility: Nanfang Hospital of Southern Medical University
state: Guangdong
city: Nanyang
country: China
facility: The First Affiliated Hospital of Nanyang Medical College
state: Henan
city: Changsha
country: China
facility: Xiangya Hospital Central-South University
state: Hunan
city: Nanjing
country: China
facility: Local Institution - 804
state: Jiangsu
city: Nantong
country: China
facility: Local Institution - 818
state: Jiangsu
city: Nanchang
country: China
facility: Local Institution - 820
state: Jiangxi
city: Nanchang
country: China
facility: Nanchang University - The Second Affiliated Hospital
state: Jiangxi
city: Qingdao
country: China
facility: Local Institution - 821
state: Shandong
city: Taiyuan
country: China
facility: Local Institution - 816
state: Shanxi
city: Kunming
country: China
facility: The Second Affiliated Hospital Of Kunming Medical University
state: Yunnan
city: Beijing
country: China
facility: Beijing Peking Union Medical College Hospital
city: Changchun
country: China
facility: Local Institution - 802
city: Guangzhou
country: China
facility: Guangdong General Hospital
city: Harbin
country: China
facility: The First Affiliated Hospital Of Harbin Medical University
city: Shanghai
country: China
facility: Local Institution - 809
city: Shanghai
country: China
facility: Local Institution - 801
city: Suzhou
country: China
facility: Local Institution - 811
city: Tianjin
country: China
facility: Local Institution - 800
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
city: Zhengzhou
country: China
facility: Local Institution - 810
city: Medellin
country: Colombia
facility: Local Institution - 161
state: Antioquia
city: Bogota
country: Colombia
facility: Local Institution - 163
state: Distrito Capital De Bogotai
city: Floridablanca
country: Colombia
facility: Local Institution - 162
state: Soto
city: Prague 2
country: Czechia
facility: Local Institution - 341
city: Angers
country: France
facility: Local Institution - 331
city: Clermont Ferrand
country: France
facility: Local Institution - 333
city: Creteil
country: France
facility: Local Institution - 324
city: Grenoble
country: France
facility: Chu De Grenoble
city: Lille
country: France
facility: Local Institution - 327
city: Lyon
country: France
facility: Local Institution - 332
city: Nice
country: France
facility: CHU de Nice Archet I
city: Nimes Cedex 9
country: France
facility: Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
city: Paris Cedex 10
country: France
facility: Hopital Saint Louis
city: Pessac
country: France
facility: Groupe Hospitalier Sud Hopital Haut Leveque USN
city: Poitiers Cedex
country: France
facility: CHU La Miletrie
city: Strasbourg
country: France
facility: ICANS Institut de cancerologie Strasbourg Europe
city: Toulouse Cedex 9
country: France
facility: Local Institution - 330
city: Aachen
country: Germany
facility: Unviversitatsklinikum Aachen
city: Baden-Warttemberg
country: Germany
facility: Stauferklinikum Schwab. Gmund
city: Dusseldorf
country: Germany
facility: Local Institution - 299
city: Halle
country: Germany
facility: Universitatsklinikum Halle Saale
city: Hamburg
country: Germany
facility: Local Institution - 300
city: Jena
country: Germany
facility: Universitaetsklinikum Jena
city: Leipzig
country: Germany
facility: Local Institution - 297
city: Mannheim
country: Germany
facility: Local Institution - 301
city: Minden
country: Germany
facility: Johannes Wiesling Klinikum Minden
city: Patra
country: Greece
facility: Local Institution - 387
state: Achaia
city: Alexandroupolis
country: Greece
facility: Local Institution - 383
city: Athens
country: Greece
facility: Evangelismos General Hospital of Athens
city: Athens
country: Greece
facility: Local Institution - 386
city: Athens
country: Greece
facility: Attikon University General Hospital
city: Rio Patras
country: Greece
facility: University General Hospital of Patras
city: Thessaloniki
country: Greece
facility: Georgios Papanikolaou General Hospital of Thessaloniki
city: Hong Kong
country: Hong Kong
facility: Local Institution - 661
city: Sha Tin
country: Hong Kong
facility: Prince of Wales Hospital the Chinese University of Hong Kong
city: Budapest
country: Hungary
facility: Local Institution - 462
city: Gyor
country: Hungary
facility: Local Institution - 463
city: Cork
country: Ireland
facility: Cork University Hospital
city: Dublin 7
country: Ireland
facility: Mater Misercordiae Hospital
city: Dublin
country: Ireland
facility: St James Hospital
city: Tel-Aviv
country: Israel
facility: Tel-Aviv Sourasky Medical Center
state: Tel Aviv
city: Haifa
country: Israel
facility: Rambam Medical Center
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
city: Kfar-Saba
country: Israel
facility: Meir Medical Center
city: Zerifin
country: Israel
facility: Shamir Medical Center - Assaf Harofeh
city: Meldola (fc)
country: Italy
facility: IRCCS - Istituto Romagnolo per lo Studio Dei Tumori "Dino Amadori" (IRST)
state: Fc
city: Ancona
country: Italy
facility: Local Institution - 250
city: Bologna
country: Italy
facility: Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
city: Brescia
country: Italy
facility: Asst Spedali Civili Di Brescia
city: Catania
country: Italy
facility: Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico
city: Firenze
country: Italy
facility: Azienda Ospedaliera Universitaria Careggi
city: Milano
country: Italy
facility: Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
city: Napoli Campania
country: Italy
facility: Local Institution - 246
city: Novara
country: Italy
facility: A.O.U. Maggiore della Carit
city: Padova
country: Italy
facility: Azienda Ospedaliera Di Padova
city: Pisa
country: Italy
facility: Local Institution - 248
city: Reggio Di Calabria
country: Italy
facility: Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
city: Roma
country: Italy
facility: Azienda Policlinico Universitario Umberto I
city: Roma
country: Italy
facility: Local Institution - 251
city: Roma
country: Italy
facility: Local Institution - 249
city: Terni
country: Italy
facility: Local Institution - 245
city: Torino
country: Italy
facility: Local Institution - 259
city: Varese
country: Italy
facility: Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese
city: Verona
country: Italy
facility: Centro Ricerche Cliniche di Verona S.r.l.
city: Nagasaki-shi
country: Japan
facility: The Japanese Red Cross Nagasaki Genbaku Hospital
state: Nagasaki
city: Osakasayama
country: Japan
facility: Kindai University Hospital- Osakasayama Campus
state: Osaka
city: Bunkyo-ku
country: Japan
facility: Local Institution - 701
state: Tokyo
city: Chuo
country: Japan
facility: Local Institution - 709
state: Yamanashi
city: Aomori
country: Japan
facility: Aomori Prefectural Central Hospital
city: Bunkyo-ku
country: Japan
facility: Local Institution - 713
city: Isehara City, Kanagawa
country: Japan
facility: Tokai University Hospital
city: Kamakura
country: Japan
facility: Local Institution - 717
city: Kamogawa
country: Japan
facility: Kameda General Hospital
city: Maebashi
country: Japan
facility: Local Institution - 706
city: Miyazaki
country: Japan
facility: University of Miyazaki Hospital
city: Ogaki
country: Japan
facility: Ogaki Municipal Hospital
city: Osaka
country: Japan
facility: Osaka Metropolitan university Hospital
city: Sapporo
country: Japan
facility: Local Institution - 708
city: Shinagawa-ku, Tokyo
country: Japan
facility: NTT Medical Center Tokyo
city: Shinjuku City
country: Japan
facility: Tokyo Women's Medical University Hospital
city: Shinjyuku-ku
country: Japan
facility: Local Institution - 710
city: Toyohashi
country: Japan
facility: Toyohashi Municipal Hospital
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Hospital
city: Hwasun-Gun
country: Korea, Republic of
facility: Chonnam National University Hwasun Hospital
city: Seongnam-si
country: Korea, Republic of
facility: Local Institution - 643
city: Seoul
country: Korea, Republic of
facility: Local Institution - 647
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea Seoul - Saint Mary's Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Saida
country: Lebanon
facility: Local Institution - 551
state: South
city: Badaro Beirut
country: Lebanon
facility: Local Institution - 550
city: Beirut
country: Lebanon
facility: Local Institution - 552
city: Gdansk
country: Poland
facility: Local Institution - 436
city: Krakow
country: Poland
facility: Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
city: Lodz
country: Poland
facility: Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
city: Poznan
country: Poland
facility: Local Institution - 433
city: Walbrzych
country: Poland
facility: Specjalistyczny Szpital im. dra Alfreda Sokolowskiego
city: Wroclaw
country: Poland
facility: Local Institution - 435
city: Craiova
country: Romania
facility: Local Institution - 395
state: Dolj
city: Brasov
country: Romania
facility: Onco Card SRL
city: Bucharest
country: Romania
facility: Local Institution - 391
city: Cluj-Napoca
country: Romania
facility: Prof. Dr. I. Chiricuta Institute of Oncology
city: Moscow
country: Russian Federation
facility: Local Institution - 500
city: St Petersburg
country: Russian Federation
facility: Local Institution - 502
city: St. Petersburg
country: Russian Federation
facility: Local Institution - 503
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
city: Barcelona
country: Spain
facility: Hospital Universitari Germans Trias i Pujol ICO Badalona
city: Granada
country: Spain
facility: Local Institution - 208
city: Las Palmas de Gran Canaria
country: Spain
facility: Hospital Universitario De Gran Canaria Dr. Negrin
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
city: Madrid
country: Spain
facility: Hospital Universitario 12 De Octubre
city: Palma de Mallorca
country: Spain
facility: Local Institution - 202
city: Salamanca
country: Spain
facility: Universitario de Salamanca - Hospital Clinico
city: Santiago de Compostela
country: Spain
facility: Complejo Hospitalario Universitario De Santiago
city: Seville
country: Spain
facility: Hospital Universitario Virgen del Rocio
city: Valencia
country: Spain
facility: Hospital Clinico Universitario De Valencia
city: Nottingham
country: United Kingdom
facility: Nottingham City Hospital
state: Nottinghamshire
city: Birmingham
country: United Kingdom
facility: Heart of England NHS Foundation Trust
city: Boston
country: United Kingdom
facility: United Lincolnshire Hospitals NHS Trust
city: Oxford
country: United Kingdom
facility: Churchhill Hospital
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: